Altered expression of α-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy

Kimiko Suzue, Anthony G. Montag, Maria Tretiakova, Ximing J. Yang, Sunati Sahoo

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

α-Methylacyl-coenzyme A racemase (AMACR) is a sensitive and specific tissue marker for the diagnosis of prostatic carcinoma. However, limited data are available on AMACR expression in residual prostatic carcinoma following hormone therapy. We analyzed 64 residual or recurrent prostatic adenocarcinomas following hormonal therapy for the expression of AMACR using a monoclonal antibody (P504S) to AMACR. In 20 localized cases, AMACR staining was absent in 11 (55%), 1+ in 6 (30%), and 2+ or 3+ in 3 (15%). However, in 15 metastatic cases, AMACR was absent in 1 (7%), 1+ in 3 (20%), and 2+ or 3+ in 11 (73%). None of the 29 postradiotherapy cases showed complete absence of AMACR staining: 2 (7%) were 1+, and 27 (93%) were 2+ or 3+. AMACR expression was reduced significantly in the majority of posthormonal residual carcinomas, whereas in postradiotherapy and in hormone-refractory metastatic prostatic adenocarcinoma, AMACR expression was retained. Therefore, the diagnosis of residual prostatic carcinoma after hormonal therapy using AMACR immunostaining must be interpreted with caution. Furthermore, AMACR might have a role in the recurrence of prostatic adenocarcinoma after medical therapy.

Original languageEnglish (US)
Pages (from-to)553-561
Number of pages9
JournalAmerican Journal of Clinical Pathology
Volume123
Issue number4
DOIs
StatePublished - Apr 2005

Fingerprint

Racemases and Epimerases
Coenzyme A
Adenocarcinoma
Hormones
Carcinoma
Staining and Labeling
Therapeutics
Monoclonal Antibodies
Recurrence

Keywords

  • α-Methylacyl-coenzyme A racemase
  • AMACR
  • Hormone therapy
  • Prostate carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Altered expression of α-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy. / Suzue, Kimiko; Montag, Anthony G.; Tretiakova, Maria; Yang, Ximing J.; Sahoo, Sunati.

In: American Journal of Clinical Pathology, Vol. 123, No. 4, 04.2005, p. 553-561.

Research output: Contribution to journalArticle

Suzue, Kimiko ; Montag, Anthony G. ; Tretiakova, Maria ; Yang, Ximing J. ; Sahoo, Sunati. / Altered expression of α-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy. In: American Journal of Clinical Pathology. 2005 ; Vol. 123, No. 4. pp. 553-561.
@article{98cd46d8e2ba492bbca1e1e98a88b6a9,
title = "Altered expression of α-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy",
abstract = "α-Methylacyl-coenzyme A racemase (AMACR) is a sensitive and specific tissue marker for the diagnosis of prostatic carcinoma. However, limited data are available on AMACR expression in residual prostatic carcinoma following hormone therapy. We analyzed 64 residual or recurrent prostatic adenocarcinomas following hormonal therapy for the expression of AMACR using a monoclonal antibody (P504S) to AMACR. In 20 localized cases, AMACR staining was absent in 11 (55{\%}), 1+ in 6 (30{\%}), and 2+ or 3+ in 3 (15{\%}). However, in 15 metastatic cases, AMACR was absent in 1 (7{\%}), 1+ in 3 (20{\%}), and 2+ or 3+ in 11 (73{\%}). None of the 29 postradiotherapy cases showed complete absence of AMACR staining: 2 (7{\%}) were 1+, and 27 (93{\%}) were 2+ or 3+. AMACR expression was reduced significantly in the majority of posthormonal residual carcinomas, whereas in postradiotherapy and in hormone-refractory metastatic prostatic adenocarcinoma, AMACR expression was retained. Therefore, the diagnosis of residual prostatic carcinoma after hormonal therapy using AMACR immunostaining must be interpreted with caution. Furthermore, AMACR might have a role in the recurrence of prostatic adenocarcinoma after medical therapy.",
keywords = "α-Methylacyl-coenzyme A racemase, AMACR, Hormone therapy, Prostate carcinoma",
author = "Kimiko Suzue and Montag, {Anthony G.} and Maria Tretiakova and Yang, {Ximing J.} and Sunati Sahoo",
year = "2005",
month = "4",
doi = "10.1309/H4JX-0XEH-DAC8-YL3P",
language = "English (US)",
volume = "123",
pages = "553--561",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "4",

}

TY - JOUR

T1 - Altered expression of α-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy

AU - Suzue, Kimiko

AU - Montag, Anthony G.

AU - Tretiakova, Maria

AU - Yang, Ximing J.

AU - Sahoo, Sunati

PY - 2005/4

Y1 - 2005/4

N2 - α-Methylacyl-coenzyme A racemase (AMACR) is a sensitive and specific tissue marker for the diagnosis of prostatic carcinoma. However, limited data are available on AMACR expression in residual prostatic carcinoma following hormone therapy. We analyzed 64 residual or recurrent prostatic adenocarcinomas following hormonal therapy for the expression of AMACR using a monoclonal antibody (P504S) to AMACR. In 20 localized cases, AMACR staining was absent in 11 (55%), 1+ in 6 (30%), and 2+ or 3+ in 3 (15%). However, in 15 metastatic cases, AMACR was absent in 1 (7%), 1+ in 3 (20%), and 2+ or 3+ in 11 (73%). None of the 29 postradiotherapy cases showed complete absence of AMACR staining: 2 (7%) were 1+, and 27 (93%) were 2+ or 3+. AMACR expression was reduced significantly in the majority of posthormonal residual carcinomas, whereas in postradiotherapy and in hormone-refractory metastatic prostatic adenocarcinoma, AMACR expression was retained. Therefore, the diagnosis of residual prostatic carcinoma after hormonal therapy using AMACR immunostaining must be interpreted with caution. Furthermore, AMACR might have a role in the recurrence of prostatic adenocarcinoma after medical therapy.

AB - α-Methylacyl-coenzyme A racemase (AMACR) is a sensitive and specific tissue marker for the diagnosis of prostatic carcinoma. However, limited data are available on AMACR expression in residual prostatic carcinoma following hormone therapy. We analyzed 64 residual or recurrent prostatic adenocarcinomas following hormonal therapy for the expression of AMACR using a monoclonal antibody (P504S) to AMACR. In 20 localized cases, AMACR staining was absent in 11 (55%), 1+ in 6 (30%), and 2+ or 3+ in 3 (15%). However, in 15 metastatic cases, AMACR was absent in 1 (7%), 1+ in 3 (20%), and 2+ or 3+ in 11 (73%). None of the 29 postradiotherapy cases showed complete absence of AMACR staining: 2 (7%) were 1+, and 27 (93%) were 2+ or 3+. AMACR expression was reduced significantly in the majority of posthormonal residual carcinomas, whereas in postradiotherapy and in hormone-refractory metastatic prostatic adenocarcinoma, AMACR expression was retained. Therefore, the diagnosis of residual prostatic carcinoma after hormonal therapy using AMACR immunostaining must be interpreted with caution. Furthermore, AMACR might have a role in the recurrence of prostatic adenocarcinoma after medical therapy.

KW - α-Methylacyl-coenzyme A racemase

KW - AMACR

KW - Hormone therapy

KW - Prostate carcinoma

UR - http://www.scopus.com/inward/record.url?scp=15744394110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15744394110&partnerID=8YFLogxK

U2 - 10.1309/H4JX-0XEH-DAC8-YL3P

DO - 10.1309/H4JX-0XEH-DAC8-YL3P

M3 - Article

C2 - 15743746

AN - SCOPUS:15744394110

VL - 123

SP - 553

EP - 561

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 4

ER -